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Background: Prostate cancer is a growing health problem worldwide. The management of localised prostate
cancer is controversial. It is unclear which of several surgical, radiotherapeutic, ablative, and surveillance treatments
is the most effective. All have cost, process and recovery, and morbidity implications which add to treatment
decision-making complexity for patients and healthcare professionals. Evidence from randomised controlled trials
(RCTs) is not optimal because of uncertainty as to what constitutes important outcomes. Another issue hampering
evidence synthesis is heterogeneity of outcome definition, measurement, and reporting. This project aims to determine
which outcomes are the most important to patients and healthcare professionals, and use these findings to recommend
a standardised core outcome set for comparative effectiveness trials of treatments for localised prostate cancer, to optimise
decision-making.
Methods/Design: The range of potentially important outcomes and measures will be identified through systematic reviews
of the literature and semi-structured interviews with patients. A consultation exercise involving representatives from two key
stakeholder groups (patients and healthcare professionals) will ratify the list of outcomes to be entered into a three round
Delphi study. The Delphi process will refine and prioritise the list of identified outcomes. A methodological substudy (nested
RCT design) will also be undertaken. Participants will be randomised after round one of the Delphi study to one of three
feedback groups, based on different feedback strategies, in order to explore the potential impact of feedback strategies on
participant responses. This may assist the design of a future core outcome set and Delphi studies. Following the Delphi study,
a final consensus meeting attended by representatives from both stakeholder groups will determine the final recommended
core outcome set.
Discussion: This study will inform clinical practice and future trials of interventions of localised prostate cancer by
standardising a core outcome set which should be considered in comparative effectiveness studies for localised
prostate cancer.
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Prostate cancer is the second most common male cancer
worldwide (an estimated 1.1 million cases diagnosed in
2012), and the fourth most common cancer overall [1].
It is the fifth most common cause of cancer death in
males worldwide (307,000 deaths in 2012), and about
70% of registered cases (759,000) occur in more devel-
oped regions (Western and Northern Europe, Australia,
New Zealand, North America, Polynesia, and the
Caribbean) [1]. Incidence and mortality rates are gen-
erally high in predominantly black populations and
very low in Asia, suggesting a possible genetic deter-
minant [2-4]. The worldwide burden is expected to
grow due to global population growth and ageing [3].
In contrast to the rising incidence, mortality rates
have decreased in most high resource settings (includ-
ing North America, Northern and Western Europe,
and Oceania).
Prostate cancer is the most common cancer in men in
the United Kingdom [5]. In 2010, nearly 41,000 new
cases were reported; a quarter of all new male cancer
diagnoses [5]. The incidence of prostate cancer is rising
[5,6] due to increasing use of prostate specific antigen
(PSA) testing [5-7] and the ageing population [8]. The
largest rise in incidence is in men with localised prostate
cancer [5]. Prostate cancer causes 13% (10,721) of
cancer-related deaths each year [9]. The total costs for
prostate cancer for the United Kingdom in 2009
(encompassing treatment costs for surgery, radiotherapy,
hospital and community care, premature deaths, time off
work, and unpaid care to patients by family and friends),
were estimated at approximately £800 million per
annum [10]. Consequently, prostate cancer represents a
significant healthcare burden for the United Kingdom.
In the United Kingdom, more than 4,000 radical pros-
tatectomies are carried out annually [11]. Of these, the
majority are open procedures, although laparoscopic and
robotic-assisted techniques are increasingly being per-
formed [12-15], which has added to the ongoing di-
lemma for surgeons, patients, and health services when
making treatment choices. Radical prostatectomy is as-
sociated with significant morbidity and incurs substantial
health service costs. Consequently, there is an urgent
need for high quality evidence, including well designed
and properly conducted randomised controlled trials
(RCTs) comparing all the major interventions for localised
prostate cancer. Some of these data will be forthcoming,
as studies comparing surgery versus non-surgical inter-
ventions, such as Prostate Testing for Cancer and Treat-
ment (ProtecT) [16] and Prostate Cancer Intervention
Versus Observation Trial (PIVOT) [17], are increasingly
being undertaken. The 10-year median follow-up period
from the PIVOT study [17] suggests that radical prostatec-
tomy does not significantly reduce all cause or prostatecancer specific mortality compared with observation, espe-
cially in low risk patients, although there is a suggestion
from the subgroup analysis that surgery may be of benefit
for intermediate and high risk patients.
Currently completed and ongoing trials are not as
helpful as they could be, due to lack of standardisation
of outcome definition, collection, and reporting [18,19].
These outcome reporting and definition problems have
been highlighted as a hindrance in evidence synthesis in
a number of localised prostate cancer intervention ef-
fectiveness systematic reviews [18,20-24]. Whilst trials of
prostate cancer interventions routinely report process-
related outcomes (such as duration of hospital stay) and
clinical outcomes (such as survival, incontinence, or
erectile dysfunction), the heterogeneity of reported out-
comes hinders comparisons of alternative interventions
for decision-making by stakeholders [20]. Oncological
outcomes such as survival, cancer progression, and can-
cer recurrence are broadly similar across the different
treatment options in the short term [21]. Hence, the
choice between treatments for patients is likely to also
be driven by other considerations such as adverse
events, impact on quality of life, patient experience of
care, patient satisfaction with care, and speed of return
to productivity or routine activities [25,26]. For clini-
cians, the choice may be influenced by learning curve is-
sues and outcomes such as positive margin [27] and
PSA recurrence rates [28]. The lack of consistency and
clarity of what outcomes should be measured and re-
ported hampers decision-making by all stakeholders.
For researchers, the design of RCTs is compromised at
various stages, including sample size calculations, and
potentially important outcomes not being measured,
analysed, or reported, resulting in outcome reporting
bias [19]. For the NHS in the United Kingdom, the lack
of reliable cost-effectiveness data hinders decision-making.
For patients and healthcare professionals, shared decision-
making in terms of understanding the risks and benefits of
the different treatment options is compromised, informed
consent is hampered, clinical governance becomes prob-
lematic, and participation in RCTs becomes difficult.
Hence, there is an urgent need to identify a core outcome
set of universal importance, which reflects the perspectives
of all stakeholders. A core outcome set is defined to be ‘an
agreed standardised set of outcomes that should be mea-
sured and reported, as a minimum, in all clinical trials in
specific areas of health or health care’ [29].
The Core Outcome Measures in Effectiveness Trials
(COMET) initiative was launched in January 2010 [30]
to address the lack of standardised core outcome mea-
sures in clinical trials. COMET has searched the litera-
ture to identify studies which have developed outcome
sets in a variety of conditions, and maintains a database
[31,32]. The database includes 12 studies relevant to
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localised prostate cancer. Although all of these studies
make recommendations for a localised prostate cancer-
specific core outcome set, all have various methodological
flaws, such as: not including patients in the consultation
process [33,34], relying solely on literature reviews for the
generation and recommendation of outcomes with no pri-
mary research to propose or prioritise outcomes [34-37],
focusing on treatment decisions by patients and ignoring
post-intervention experience and outcomes suggested by
clinicians [36], or including only a clinical expert and/or
guideline panel participants and no patients [34,35,37].
One study by the International Consortium for Health
Outcomes Measurement (ICHOM) [38,39] did include
two patient representatives, but the methods for priori-
tising and achieving consensus on which outcomes to
include and how patients were involved were not trans-
parent. Furthermore, ICHOM’s focus is toward routine
data collection in clinical practice, with a view to com-
paring healthcare providers’ outcomes in a competitive
sense, as opposed to providing a core outcome set for
use in effectiveness trials. The present research represents
a robust attempt at involving healthcare professional and
patient stakeholders, and developing a localised prostate
cancer-specific core outcome set for use in effectiveness
trials using standardised and validated methodology, in
close collaboration with COMET. Furthermore, we have
included a nested RCT within the Delphi phase of this re-
search project in order to investigate how differences in
how outcomes are scored might be affected by the feed-
back participants have access to. This may assist COMET
and other core outcome set development projects in de-
signing future Delphi projects.
Aims and objectives
Aim
The overall aim of this project is to develop a core out-
come set for localised prostate cancer effectiveness trials
which recommends what outcomes should be measured,
and reflects the interests of patients and healthcare pro-
fessionals, in order to facilitate decision-making.
Objectives
The specific objectives are: (1) to identify a list of out-
comes from published studies reporting on any thera-
peutic intervention for localised prostate cancer; (2) to
determine the heterogeneity of outcome definitions, and
the number of different measuring instruments used and
the specific ways in which they differ; (3) to identify a list
of potentially important outcomes reported by men who
have been treated for localised prostate cancer in order
to augment the list generated from (1); (4) to prioritise
and reach consensus regarding the most important out-
comes from the perspective of patients and healthcareprofessionals into a core outcome set; and (5) to investi-
gate how differences in Delphi study outcome scoring
might be affected by the feedback participants have ac-
cess to in order to assist the design of future Delphi
studies.
Methods/Design
The project will be divided into two distinct phases: (1)
generation of a list containing all possible relevant out-
comes (systematic review of the literature and semi-
structured interviews with patients); and (2) prioritisation
of important outcomes from stakeholder groups (patients
and healthcare professionals; Delphi study for each group),
followed by integration of outcomes into a core outcome
set (consensus group meeting).
Phase one: generation of a list containing all possible
relevant outcomes
Systematic review
Research question: What are the outcomes reported in
studies assessing the effectiveness of interventions for
localised prostate cancer?
Study overview and method This study will consist of
a systematic review of studies of the effects of surgery
(open, laparoscopic, and robotic-assisted radical prostatec-
tomy), radiotherapy, brachytherapy, and active monitoring
for localised prostate cancer. Patient care pathways (see
Additional file 1) have been established with consensus
from international clinical content experts; these will pro-
vide a conceptual framework to identify potential out-
comes [40].
Types of studies We intend to limit included studies to
those that are likely to influence clinical practice. For
this reason, the Oxford Centre for Evidence Based Medi-
cine’s guidelines regarding hierarchy of evidence [41] will
be adhered to. Accordingly, where the list of identified
studies includes more than one RCT for an intervention
and comparator pair, we will include only the RCT.
When there is only one or there are no RCTs in the
identified studies list, we will include non-randomised
comparative studies, and where there are only single-
arm case series (which are more likely for newer inter-
ventions or technologies) we will include these. Where
non-randomised studies have been included and RCTs
are found in subsequent updates, we will retain the non-
randomised studies. Ongoing trials (identified in trial
registers) will also be included. It is possible that includ-
ing all types of study design would yield a larger number
of outcomes that could perhaps reflect the views of all
stakeholders more comprehensively. However, subsequent
parts of the research, such as patient interviews (outlined
below), and the Delphi study (outlined below), provide
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garding potentially important outcomes are considered.
Types of interventions Interventions considered for
this review are: surgery (open, laparoscopic, or robotic,
incorporating any approach and technique); external
beam radiotherapy (EBRT), three-dimensional conformal
radiotherapy (3D-CRT), or intensity modulated radio-
therapy (IMRT), incorporating any dose or schedule;
brachytherapy (permanent or temporary seed implant-
ation, incorporating any dose or schedule); cryotherapy;
high intensity focussed ultrasound (HIFU) active surveil-
lance or monitoring; and watchful waiting or observation.
Types of participants The participants are men of any
age with clinically localised prostate cancer (defined as
cT1-2c N0 M0, according to the TNM classification of
malignant tumours) [42].
Exclusion criteria In studies where more than 20% of
the population are not clinically localised (>cT2c, or N+
or M+), the study will be excluded. Studies of dietary in-
terventions will be excluded. Studies with fewer than 10
patients per intervention arm will be excluded because
they are unlikely to influence practice.
Search methods for identification of studies The re-
view will be reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [43]. We will include
studies identified from four existing systematic reviews
which have similar inclusion criteria to this research
[20,28,44]. The excluded studies lists from these reviews
will be screened to minimise the possibility that some of
these studies were excluded on the basis of not reporting
outcomes of interest. We will not re-screen original ab-
stract lists because it is very unlikely that reviewers
would have excluded on the basis of outcome during ab-
stract screening. Update searches of the existing reviews
will also be performed and any further studies which
meet inclusion criteria (outlined below) will be included.
Eligibility of studies Two review authors (SM and
TBLL) will independently assess the abstracts returned
from the searches. Full texts of all potentially relevant
studies will be obtained. Any studies not meeting inclu-
sion criteria will be excluded. Where a resolution cannot
be reached, a third review author (JMOND) will be
consulted.
Data extraction Data will be extracted independently
by two review authors (SM and HB) and checked by a
third author (TBLL). SM and TBLL will then review the
extracted data to assess consensus and ensure alloutcomes have been identified. The following data will
be extracted from each study: study type, author details,
year and journal of publication, intervention(s) under in-
vestigation, each effectiveness outcome reported, whether
the outcome was defined or not, the definition used, the
indicators and/or tool(s) used to operationalize or measure
the outcome, the time point or period of outcome meas-
urement, and how the outcome was reported. Disagree-
ment will be resolved through discussion; where a
resolution is not possible a third reviewer (JMOND) will
be consulted. We will contact study authors to identify
any unclear and/or unavailable data.
Data analysis and presentation The data will be en-
tered into Microsoft Excel in order to aid tabulation and
analysis. Outcomes will be grouped under domains fol-
lowing a review of the outcomes by TBLL and SM. Out-
comes regarded as ‘harmful effects’ will be grouped
within the domain ‘Adverse Events’. The outcome do-
mains and included outcomes will be reviewed by the
Study Advisory Group to assess the suitability of the do-
main name and outcomes grouping. We will then evalu-
ate how many outcomes have been used to reflect each
domain, and how many different definitions and mea-
surements were used.
Semi-structured interviews with individual patients
Research question: What are the outcomes patients re-
gard as potentially important following treatment for
localised prostate cancer?
Study overview and method
Semi-structured interviews with patients who have had
treatment for localised prostate cancer. Semi structured
interviews have been used effectively to ascertain the pa-
tient perspective in previous COMET and Outcome
Measures in Rheumatology (OMERACT) studies [45,46].
We anticipate that intervention type, age at intervention,
and time since intervention will influence the outcomes
patients regard as potentially important. We will purpos-
ively sample to cover a wide range of available interven-
tions for localised prostate cancer, age at intervention, and
time since intervention. An initial analysis sample of 15
will be recruited because there are relatively few stratifica-
tion factors (akin to independent variables), and we will
use a stopping criterion of three [47]. That is, a wide range
of idiosyncratic and common outcomes (reported by at
least two patients) are anticipated to be discernible within
12 interviews; if no new common outcomes emerge after
interview 15, data saturation can be demonstrated. If new
common outcomes are identified within the three add-
itional interviews, we will conduct a further three inter-
views, and so on until no new outcomes are reported.
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treatment type, time since intervention, and age at time
of intervention. Each participant will be given an infor-
mation booklet outlining the study. Following this, con-
sent will be obtained from each participant by attaining
their signature on a consent form which outlines that
they understand the purpose of the study, the uses their
data will be put to, and their right to withdraw at any
point. Interviews will be audio-recorded and transcribed
in full. Coding of the data will proceed using a thematic
analysis approach and emerging themes identified, whilst
paying attention to the number of idiosyncratic and
shared outcomes reported. The data will be checked for
validity and contextual accuracy to compile a list of im-
portant outcomes.
Analysis of semi-structured interviews Audio record-
ings of the semi-structured interviews will be fully tran-
scribed, stored, and analysed using NVivo10 software
(QSR International, Burlington, Massachusetts, United
States) and themes will be derived from issues raised by
participants. To aid analysis, an adapted framework
method of data management [48] will be used in order
to chart the coded data. This will also enable the identi-
fication of additional new codes. In this way, important
information will be identified from a large amount of
data in a structured fashion, which will enable recogni-
tion of when data saturation has been reached and will
inform stopping criterion strategy.
Consultation exercise
Research question: From the list of outcomes identified
from the systematic review and semi-structured inter-
views with patients, what are the outcomes that should
be entered into phase two for further study?
Study overview and method
Consultation exercise with patients. The list of outcomes
identified from the literature review and from the semi-
structured interviews with patients will be combined,
and the objective of the consultation exercise is to ratify
the outcomes to ensure clear and efficient meanings are
given, and that there is no duplication. This ratified
comprehensive list of outcomes will be entered into
phase two. The consultation exercise will include the re-
search team (TBBL, JMOND, and SM); the steering
group (Professor Marion Campbell, Professor Craig
Ramsay, Professor Luke Vale, Professor Paula Williamson,
and Professor Vikki Entwistle), and a focus group with
seven patients (purposively sampled for a variety of treat-
ment types). Each participant will be given an information
booklet outlining the study. Following this, consent will be
obtained from each participant by attaining their signature
on a consent form which outlines that they understandthe purpose of the study, the uses their data will be put to,
and their right to withdraw at any point. A separate
healthcare professional group will not be consulted separ-
ately because their views have been covered in the system-
atic review. Furthermore, one of the project researchers
(TBLL) and one of the study advisory group members
(JMOND) are consultant urologists and can comment on
the list from a clinical perspective.
Phase two: prioritisation of important outcomes from each
stakeholder group and integration of outcomes into a core
outcome set
Research question: What are the most important out-
comes for each key stakeholder group?
Study overview
A survey of key stakeholder opinions using Delphi meth-
odology will be conducted. The list of potential out-
comes finalised from phase one will be formatted into
‘items’, with a response designed to allow the participants
to rate each of the items’ value for the final core out-
come set, with high scores indicating the importance of
inclusion. An online questionnaire will be developed for
the Delphi process and piloted for each key stakeholder
group (patients and healthcare professionals, consisting
of clinicians and specialist nurses). It is anticipated that
each Delphi process will consist of three rounds, with
participants numbering up to 150 for the patient and
healthcare professional groups. Although there is no
consensus regarding the appropriate sample size used in
Delphi methodology, we will draw upon the experience
from previous Delphi studies [46,49,50], and also be
guided by COMET. Items addressing similar constructs
will be worded and phrased accordingly for both groups
of participants to ensure understanding. Patients will be
locally recruited from the north of Scotland prostate
cancer patient support group (Urological Cancer Charity
(CAN)) and nationally from patient-led support groups
that are members of the umbrella organisation Prostate
Cancer Support Federation (PCSF).
The healthcare professional group will comprise of
localised prostate cancer specialist nurses, consultant
clinical and medical oncologists, and consultant urological
surgeons currently undertaking all types of radical prosta-
tectomy or other therapies for localised prostate cancer
(including cryotherapy and HIFU). They will be identified
and recruited through the British Association of Uro-
logical Surgeons (BAUS), and the group will be comple-
mented by British and international experts (from Europe
and the United States) in open retropubic, laparoscopic,
and robotic radical prostatectomy, and minimally invasive
ablative therapies (including cryotherapy and HIFU), with
whom our group has collaborated with on several Na-
tional Institute for Health Research, Health Technology
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tematic reviews on the clinical effectiveness of interven-
tions for localised prostate cancer [20,28]. Each participant
will be emailed information outlining the study. Informed
consent will be assumed if participants register for the on-
line Delphi questionnaire and submit their answers.
A nested RCT will also be included within the Delphi
study. Randomisation into one of three groups will be
performed when a participant logs on to round two.
From their round one data it will be known which of the
two stakeholder groups they are in (effectively stratifying
by stakeholder group). It is intended that variable block
randomisation will be used. Group one will have access
to their own stakeholder group’s scores only as feedback,
group two will have access to their own stakeholder
group’s and the other stakeholder group’s scores, and
group three will have access to both stakeholder groups’
scores combined. The main outcome of interest for the
nested RCT is the difference between elements of the
core outcome sets developed in each randomised group.
To maximise the information gained from the multiple
consensus exercises in the final core outcome set, all re-
sults will be considered at the final consensus meeting.
If the trial finds no obvious differences between the ap-
proaches, it would not be inferred that they are intrinsic-
ally the same, or that this finding could be applied in
other settings (since it could be due to inadequate power
or homogeneity of opinion in the studied area); but if
important differences are detected, this may have im-
portant implications for the future development of core
outcome sets [51,52].
Study method
Delphi study round one Email addresses for potential
participants will be collected by the research team via
contacting prostate cancer specific patient-led support
groups and charities throughout the United Kingdom
(for the patient group), and national and international
professional bodies such as BAUS and the European As-
sociation of Urologists (EAU) (for the healthcare profes-
sionals group). Each participant will be sent an online
questionnaire. Their name and email address will be
used to generate unique identifiers which enable identifi-
cation of all participants completing each round of the
Delphi study. Participants will be asked to complete the
Delphi questionnaire within three weeks and will be
prompted after week two with an email reminder. The
Delphi questionnaires will contain lay terminology which
will be listed alongside clinical terms to assist patients in
understanding complex terminology (such as positive
surgical margins).
Participants will be required to identify which stake-
holder group they belong to using a dropdown menu. Inaddition, within each stakeholder group there will be
further categories to choose from these dropdown
menus. For instance, the patient group will be required
to identify their age group (older than 60 or younger
than 60), the intervention they received (open surgery,
EBRT, active surveillance, and so forth), and the time
since their intervention (more than one year ago or less
than one year ago). Healthcare professionals will be
asked to identify their role (specialist nurse, laparoscopic
surgeon, robotic surgeon, open radical prostatectomy
surgeon, cryotherapist or HIFU specialist, radiation on-
cologist, brachytherapy oncologist, and so forth).
In round one, the participants will be asked to con-
sider treatment decisions and the benefits and adverse
events associated with treatment. Separate instructions
and guidance will be provided for healthcare profes-
sionals and patients via an online link to allow tailoring
of the language (technical versus lay) to describe terms.
For the questionnaire, identical questions will be used
for healthcare professionals and patients alike: ‘How im-
portant are the following outcomes in making decisions
regarding prostate cancer treatment?’.
Participants will be asked to score the importance of
each of the outcomes listed on a nine-point scale (scores
grouped into one to three = not important; four to six =
important but not critical; or seven to nine = critical; as
well as an ‘unable to score’ option). This scale was de-
vised by the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) to score the
quality of evidence for outcomes in systematic reviews
and has been adopted in other core outcome develop-
ment research groups using Delphi methods [49]. Round
one will also provide an option for any participant to
add any additional outcomes. Non-responders will not
be invited to participate in round two.
Analysis of Delphi study round one Descriptive statis-
tics will summarise the results of round one, including
the percentage of participants scoring the outcome at
each possible response from one to nine. Any additional
outcomes identified by participants that are deemed to
represent a new outcome by the researchers (TL and
SM) will be included for round two, and any uncertain-
ties will be discussed with the study advisory group. All
outcomes will be carried forward to round two.
Delphi study round two
Participants will complete round two online. All partici-
pants will be reminded of their own round one scores.
Participants will be randomised to one of three groups
as follows:
1. Group one (consisting of a third of the patient
stakeholder group and a third of the healthcare
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will be shown the proportion of people in their own
stakeholder group choosing each score from one to
nine.
2. Group two (consisting of another third of the
participants from each stakeholder group, randomly
allocated) will be shown the proportion of people in
their stakeholder group choosing each score from
one to nine and the other stakeholder group’s scores.
3. Group three (consisting of the remaining third from
each stakeholder group) will shown both stakeholder
groups’ scores combined.
Participants will be asked to re-score the outcomes.
All outcomes from round one will be carried forward.
Analysis of Delphi study round two The proportion of
participants scoring the outcome at each possible re-
sponse from one to nine will be used to summarise
round two. All outcomes will be carried forward to
round three.
Delphi study round three Round three will also be
completed online. All participants will be reminded of
their round two scores. If response rates number at least
10 per stakeholder group per arm, participants will be
retained in their randomised feedback groups one, two,
and three, and will only have access to the feedback
scores from others randomised to their group. If re-
sponse rates are poor then the randomised groups one,
two, and three will be shown feedback from all other
participants, regardless of which group those partici-
pants were randomised to. This will be done in order to
maximise information. Participants will be asked to re-
score the outcomes.
Analysis of Delphi study round three For each out-
come presented in round three, the proportion of partic-
ipants from each stakeholder group scoring one to three,
four to six, and seven to nine on the nine-point Likert
scale will be calculated for each item regardless of ran-
domised group. ‘Consensus in’ (consensus that the out-
come should be included in core set) will be defined as
greater than 70% of participants scoring between seven
and nine and less than 15% of participants scoring be-
tween one and three. ‘Consensus out’ (consensus that
the outcome should not be included in core set) will be
defined as greater than 70% of participants scoring be-
tween one to three and less than 15% of participants
scoring between seven and nine. All other combinations
will be considered ‘equivocal’. The outcomes that are
designated as ‘consensus in’ by both stakeholder groups
will be included in the final core outcome set to becarried forward to the consensus meeting. Results for all
outcomes will be presented at the consensus meeting,
including those designated ‘consensus out’ by both
stakeholder groups, in order to remind the stakeholders
what the result of the Delphi process was.
The nested RCT will be analysed to ascertain whether
participants having seen feedback from their group only,
the other group’s feedback only, or their own group’s
and the other group’s feedback alters scoring.
Consensus group meeting
Research question: Can we derive a core outcome set
from the two sets of key outcomes from the stakeholder
groups?
Study overview A consensus meeting with key stake-
holders (patients and healthcare professionals) will be
conducted at the end of the Delphi process. The partici-
pants for the consensus group meeting will be purpos-
ively sampled to ensure a range of views of men who
have had the various treatments and the health profes-
sionals that administer them are represented. The sam-
ple for both stakeholder groups will be drawn from
those who completed all rounds of the Delphi study. All
outcomes defined as ‘consensus in’ by both stakeholders
will be accepted, all those defined ‘consensus out’ by
both stakeholders will be rejected, and all others will be
discussed at the consensus meeting. The objective of the
consensus meeting is to discuss outcomes about which
there was disagreement in round three of the Delphi
study, and to validate and agree on a final list of out-
comes which will constitute the core outcome set. A
secondary objective is to explore how treatment type
may affect outcomes regarded as important by patients.
Ethical arrangements
Ethical approval has been sought and obtained for the
project by the National Research Ethics Service (NRES)
- North of Scotland Committee (reference 12/NS0042).
Discussion
There is no published core outcome set for localised
prostate cancer effectiveness trials which has been devel-
oped in conjunction with key stakeholders using robust,
standardised, and transparent methodology. An outcome
set for routine hospital data collection, focussed on com-
parability across institutions and individual clinicians,
with a view toward lowering costs has been developed
by ICHOM [38,39]. The present research will standard-
ise core outcome definition, collection, measurement,
analysis, and interpretation in effectiveness trials for
localised prostate cancer. It will propose a core outcome
set recommending what outcomes should be measured
or at least considered in comparative clinical effectiveness
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the core outcomes set with other outcomes, because
the set represents a minimum. In addition, there may
be situations where the core outcome set may not be
relevant, especially for studies with certain specific or
focused objectives (for example, a trial designed to ascer-
tain hernia rates via different surgical interventions, or dif-
ferent vesico-urethral anastomotic suturing techniques on
duration of drainage). Nevertheless, even under such cir-
cumstances, there is an argument for such researchers to
consider if the interventions being assessed are likely to
have any impact on core outcomes, and if so, then to con-
sider measuring the relevant ones.
This research will benefit all stakeholders involved in
prostate cancer management in Scotland, the United
Kingdom, and beyond. Specifically, the study will have
the following long-term benefits:
1. Choice of treatments can be more fully informed by
patients’ needs, and patients will have access to
improved services including enhanced decision aids,
better counselling, full disclosure of information
during informed consent, and shared decision-making.
2. Clinicians will be better equipped to provide
informed consent and facilitate decision-making by
patients, and be able to foster improvements in clinical
governance and in the design of decision aids.
3. The NHS will be better equipped to prioritise
funding of localised prostate cancer treatments that
reflects the needs of patients.
4. Researchers will be able to design trials and
synthesise evidence which address the most
important outcomes to all stakeholders, hence
encouraging participation of clinicians and patients
in clinical trials.
In addition, the output will serve as a platform to
develop patient-reported core outcome measures for
use in clinical trials of interventions for localised pros-
tate cancer and in clinical practice. The methodology
developed will also serve as a model for the develop-
ment of core outcome measures in other urological
conditions and across other surgical specialities. The out-
put will also facilitate further studies designed to better
understand patients’ decision-making processes, through
the exploration of the weights patients give to alternative
outcomes and the trade-offs made when making a treat-
ment choice. The inclusion of key stakeholder groups in
all processes of the research ensures that the core out-
come set will be relevant to these groups and accepted as
useful in future research. The long-term objective is
to develop and validate a universal set of core out-
come measures relevant to all interventions for all
urological cancers.Trial status
Participant recruitment for the Delphi study started in
December 2014.Additional file
Additional file 1: Localised prostate cancer care pathway.Abbreviations
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